– USA, CA – Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced the appointment of Fran Schulz to its Board of Directors.
“We are excited to welcome Fran to the Senti Bio Board of Directors,” said CEO and Co-Founder, Dr. Tim Lu. “Fran’s deep expertise in the life sciences industry—spanning finance, strategic planning, operations, and transactions—will be invaluable as we drive growth and innovation across our pipeline. Fran’s track record of working with life science companies to drive financial and operational success aligns with our vision for the future, especially as Senti advances multiple clinical programs. I am confident her leadership will be instrumental in strengthening our leadership position in developing next-generation cell and gene therapies with Gene Circuits.”
Fran Schulz will join the Audit Committee as Chair.
The company also announced that Dr. Omid Farokhzad is stepping down from the Board.
About Fran Schulz
Ms. Fran Schulz was one of the founding members and senior partners in Ernst & Young’s Life Sciences Practice and has held various roles at EY for over 35 years. While at EY, she directly contributed to the growth of EY into a $45B firm recognized on the Fortune 100 Best Companies to Work For® list 22 years in a row. She is also qualified to serve as a financial expert under SEC, NYSE, and NASDAQ rules. Fran Schulz has spent her career working with large public and emerging private companies throughout the life sciences industry. She has deep experience guiding companies to execute a broad range of corporate deals including collaboration agreements, corporate spin-offs, reorganizations, and mergers and acquisitions, with personal involvement in over 100 total equity and debt transactions, raising over $15 billion in aggregate. Fran Schulz also has significant experience with the U.S. Securities and Exchange Commission and International Financial Reporting Standards.
“I am honored to join the Senti Bio Board and look forward to collaborating with such an experienced team to advance the Company’s goals,” said Fran Schulz. “Senti Bio’s commitment to Gene Circuit technologies as the foundation for developing smarter medicines is inspiring, and I am eager to contribute to its mission of creating cell therapies that outsmart complex diseases using novel and unprecedented approaches.”
Fran Schulz serves as a Board Member and Audit Committee Chair of EDAP TMS SA (Nasdaq: EDAP) and as a Board Member and Audit Committee Chair of Menlo College. Previously, she served as a Board Member, Audit Committee Chai,r, and Finance Committee Chair for the National Board of Women in Bio as well as a Board Member and an Audit Committee member for the California Life Sciences Industry Association.
Fran Schulz is a certified public accountant licensed in California. Ms. Schulz received her B.S. in Business Administration from Menlo College.
About Senti Bio
Senti Bio is a clinical-stage biotechnology company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, Senti Bio is leveraging a synthetic biology platform called Gene Circuits to create therapies with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells, ls and control the expression of drugs even after administration. The Company’s wholly-owned pipeline includes off-the-shelf CAR-NK cells, outfitted with Gene Circuits, to target challenging liquid and solid tumor indications. Senti Bio has also preclinically demonstrated that its Gene Circuits can function in T cells. Additionally, Senti Bio has preclinically demonstrated the potential breadth of Gene Circuits in other cell and gene therapy modalities, and diseases outside of oncology, and continues to advance these capabilities through partnerships with Roche/Spark Therapeutics and Bayer/BlueRock Therapeutics.
For more: https://www.sentibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.